HC Wainwright reiterated their buy rating on shares of BioHarvest Sciences (NASDAQ:BHST - Free Report) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a $14.00 price objective on the stock. HC Wainwright also issued estimates for BioHarvest Sciences' Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.27) EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.32 EPS, FY2028 earnings at $0.69 EPS and FY2029 earnings at $1.15 EPS.
Separately, Maxim Group started coverage on shares of BioHarvest Sciences in a research report on Wednesday, December 18th. They set a "buy" rating and a $12.00 price target on the stock.
Read Our Latest Analysis on BHST
BioHarvest Sciences Stock Performance
Shares of BioHarvest Sciences stock traded up $0.06 during trading on Tuesday, hitting $5.61. 28,642 shares of the stock traded hands, compared to its average volume of 10,802. The company has a market capitalization of $92.14 million, a PE ratio of -4.49 and a beta of 0.84. The business has a fifty day simple moving average of $5.73. BioHarvest Sciences has a 52 week low of $5.40 and a 52 week high of $7.38.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The firm had revenue of $7.17 million during the quarter, compared to analysts' expectations of $7.24 million. As a group, sell-side analysts expect that BioHarvest Sciences will post -0.8 earnings per share for the current year.
Institutional Investors Weigh In On BioHarvest Sciences
An institutional investor recently raised its position in BioHarvest Sciences stock. Magnus Financial Group LLC boosted its holdings in shares of BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) by 105.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,733 shares of the company's stock after purchasing an additional 36,733 shares during the quarter. Magnus Financial Group LLC owned about 0.44% of BioHarvest Sciences worth $444,000 at the end of the most recent quarter.
About BioHarvest Sciences
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
See Also
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
